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Background: Indacaterol is a novel, once-daily (od), inhaled, long-acting ß2-agonist bronchodilator for maintenance
treatment of airflow limitation in patients with COPD. The aim of this study was to evaluate the efficacy of
indacaterol on dyspnea, using available randomized placebo-controlled trials.
Methods: A systematic search was made of MEDLINE, EMBASE, the Cochrane trials databases, and a manual search
of journals. Randomized placebo-controlled trials of 12 weeks or more comparing indacaterol with placebo were
reviewed, and eligible studies were included in a meta-analysis. The odds ratio (OR) for likelihood of achieving TDI
score ≥ 1 after 12 weeks of treatment was used as an outcome measure to compare indacaterol to placebo.
Results: Six trials were included in the analysis. Relative to placebo, the overall ORs for response were: indacaterol
75 μg od 1.784 (95% CI 1.282 to 2.482); indacaterol 150 μg od 2.149 (95% CI 1.746 to 2.645); and indacaterol 300 μg
od 2.458 (95% CI 2.010 to 3.006). Overall OR for response in TDI tended to increase with higher indacaterol doses.
Conclusions: Patients receiving indacaterol had clinically significant improvements in symptoms of dyspnea
compared to placebo. Incremental benefits in TDI were observed with increasing doses. Indacaterol may provide
patients and physicians with a useful treatment option in symptomatic patients with dyspnea.
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The mortality, morbidity and economic burden of
chronic obstructive pulmonary disease (COPD) is well
documented [1,2]. Dyspnea as a cardinal symptom of
COPD is a major cause of disability and anxiety associ-
ated with the disease, prompting the medical community
to pursue effective treatments for the relief of dyspnea
[3]. Recent guidelines recommend the regular use of in-
haled long-acting bronchodilators to alleviate dyspnea in
patients with symptomatic disease, with the addition of
inhaled corticosteroids for patients who experience re-
peated exacerbations [1,2].* Correspondence: Janet_Han2000@hotmail.com
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reproduction in any medium, provided the orIndacaterol as a novel, once-daily (od), inhaled, long-
acting ß2-agonist provides sustained bronchodilation for
patients with moderate to severe COPD, with a rapid
onset following the first dose [4,5]. It has been recently
approved in Europe at doses of 150 μg and 300 μg od, in
the United States at 75 μg od, and in China at 150 μg od
for maintenance treatment of airflow limitation in pa-
tients with COPD. A number of randomized clinical tri-
als suggest that indacaterol may improve dyspnea in
patients with stable COPD, as indicated by changes in
transition dyspnea index (TDI) [5-10]. However, all of
these trials were statistically powered on forced expira-
tory volume in 1 second (FEV1) as a primary endpoint.
The outcome measure of TDI was included as one of
the secondary endpoints in these trials, and so might not
have been adequately powered.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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analysis of available randomized placebo-controlled stud-
ies to assess the efficacy of indacaterol on the important
clinical outcome of dyspnea. The objectives of this meta-
analysis were to combine data from existing randomized
placebo-controlled trials, to use the number of patients
achieving the minimum clinically important difference
(MCID) for TDI score ≥ 1 as an outcome measure, and to
evaluate the efficacy of once-daily indacaterol of licensed
75 μg, 150 μg, or 300 μg doses relative to placebo on dys-
pnea in patients with stable COPD.
Methods
Data sources and selection criteria
We identified published studies between January 2007
and May 2012 from MEDLINE, EMBASE, and the
Cochrane Controlled Trials Register (CENTRAL) data-
bases using the terms indacaterol, long-acting ß2 -agonist
AND chronic obstructive pulmonary disease. We
performed a search of relevant files from the Novartis
trials results database (http://www.novctrd.com/ctrdWeb
App/clinicaltrialrepository/public/login.jsp). We also per
formed a manual search of references cited in published
original and review articles, and in clinical practice
guidelines. Trials published solely in abstract form were
excluded because they contain preliminary and rudimen-
tary information and may not provide enough details to
allow full analysis. Two reviewers (JNH and LD) then in-
dependently screened potentially relevant trials from ti-
tles and abstracts. Using the full texts as necessary, the
two reviewers independently identified eligible articles
for full review. Finally, we reviewed eligible articles to
determine whether they qualified for meta-analysis. Dif-
ferences were resolved by discussion.
To be included, studies had to meet all the following
criteria: a) target population of stable COPD consistent
with American Thoracic Society/European Respiratory
Society [11] or Global Initiative for Chronic Obstructive
Lung Disease (GOLD) diagnostic criteria [12]; b) ran-
domized placebo-controlled trials comparing indacaterol
75 μg, 150 μg, or 300 μg od with placebo; c) studies
that followed patients for 12 weeks or more after
randomization; d) studies that included assessment of
dyspnea by transition dyspnea index (TDI) in outcome
measures.
Data extraction
Two reviewers independently read each article that met
inclusion criteria and performed data extraction using a
pre-designed data collection form. Missing data were
obtained from the manufacturer. Disagreement and un-
certainty were solved by discussion. Consensus was
reached for all data. Data extracted from each article in-
cluded: first author’s name and year of publication; studydesign; treatment arms; number of patients; treatment
duration; baseline clinical characteristics including age,
gender, smoking history, post-bronchodilator spirometry,
and total score of the baseline dyspnea index (BDI). The
outcome measure of TDI was recorded as total score
and as the number of patients with TDI ≥ 1.
Baseline dyspnea index (BDI) and transition dyspnea
index (TDI)
Dyspnea is often measured using the BDI and TDI, a
tool recommended by regulatory authorities for inclu-
sion in clinical trials of treatments for COPD [13]. The
BDI and TDI, as multidimensional instruments, each
has three domains: functional impairment, magnitude of
task, and magnitude of effort [14]. The BDI domains
measure baseline dyspnea severity, and are rated from 0
(severe) to 4 (unimpaired) and summed to provide a
BDI total score of 0 to 12, with a lower score indicating
more severe dyspnea. The TDI domains measure change
from the baseline dyspnea index (BDI) over time, rated
on a scale of +3 (major improvement) to −3 (major de-
terioration). The TDI has been shown to be valid, reli-
able and responsive [14,15]. The minimum clinically
important difference (MCID) for the TDI is an improve-
ment from the BDI score of ≥1 unit [16,17].
Statistical analyses
Odds ratio (OR) for likelihood of achieving TDI score
≥1 after 12 weeks of treatment was used as a measure to
compare indacaterol relative to placebo. We calculated
pooled ORs with the DerSimonian-Laird random effects
model [18], usually regarded as more appropriate than
other statistical approaches when potential heterogeneity
is present between studies [19,20]. We performed separ-
ate analyses for indacaterol 75 μg versus placebo, inda-
caterol 150 μg versus placebo, and indacaterol 300 μg
versus placebo. We calculated the 95% confidence inter-
vals around the ORs, and assessed heterogeneity across
studies with the chi-square test and I2 (p < 0.10, I2 >
25%). We then created forest plots of the individual
studies and combined estimates. All analyses were
performed with meta-analysis software (MetaAnalyst
version beta 3.13, Tufts Medical Center, Boston,
Massachusetts).
Results
Characteristics of included studies
Six studies met the inclusion criteria [5-9], the de-
signs of which are summarized in Table 1. The
studies varied from 12 to 52 weeks in duration, and
so to permit comparison across trials, assessments at
12 weeks of treatment were used for the 52-week
study [6] and for two 26-week studies [5,7]. We did
not consider data from tiotropium, formoterol, and
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od = once-daily; bid = twice-daily.
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data for each of these arms would be provided from
one study.
Table 2 illustrates patient populations and baseline
characteristics. Of the six studies providing the data
for the meta-analysis, four had similar inclusion
criteria [5-7,9], recruiting male and female patients
aged ≥40 years with a clinical diagnosis of moderate-
to-severe COPD as per the GOLD 2005 criteria and a
smoking history of ≥20 pack-years. Postbronchodilator
FEV1 was to be <80% and ≥30% predicted and
post-bronchodilator FEV1/forced vital capacity <70%
[5-7,9]. The two identical indacaterol 75 μg trials
enrolled patients with moderate-to-severe COPD de-
fined at that time using GOLD 2008 criteria, aged
≥40 years and with a smoking history of ≥10 pack-
years [8].Dyspnea – BDI and TDI
In all trials included in the meta-analysis, dyspnea was
measured at baseline using the BDI. As illustrated in
Table 2, patients had moderate severity of dyspnea at
baseline with mean BDI total scores ranging from 5.81
to 7.67. After 12 weeks of treatment, dyspnea was mea-
sured using the TDI (Table 3), which captured changes
from baseline. Data are presented as mean TDI total
scores and as the number of patients with TDI score ≥1
unit. Results were analyzed for the number of patients
responding with a change of TDI equal to or greater
than the MCID (‘responder analysis’) (Table 3).
Indacaterol 75 μg versus placebo
Two randomized placebo-controlled studies had identi-
cal entry criteria and study designs, which compared
indacaterol 75 μg once daily with placebo after 12 weeks
Table 2 Patient characteristics at baseline in the individual studies
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Data are mean (min, max) for age, smoking history, FEV1, FEV1 % predicted, and FEV1/FVC% unless stated otherwise.
a Number of patients analysed for efficacy (ITT, modified ITT or FAS).
b Post-bronchodilator spirometry.
c Values for patients who provided data at Week 12.
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studies produced a pooled OR estimate of 1.784 (95% CI
1.282–2.482) with no evidence of heterogeneity (P =
0.474, I2 = 0.000), indicating that relative to placebo,
patients receiving indacaterol 75 μg are more likely to
achieve TDI score ≥1 after 12 weeks of treatment.
Figure 1 shows a forest plot of OR estimates from these
studies.
Indacaterol 150 μg versus placebo
Three randomized placebo-controlled trials compared
indacaterol 150 μg once daily with placebo [5,7,9]. Ameta-analysis that combined the three studies produced
a pooled OR estimate of 2.149 (95% CI 1.746–2.645)
with no evidence of heterogeneity (P = 0.686, I2 =
0.000), favoring patients who received indacaterol 150μg
once daily. Figure 2 shows a forest plot of OR estimates
from these studies.
Indacaterol 300 μg versus placebo
Three trials compared indacaterol 300 μg once daily
with placebo [5,6,9]. Figure 3 shows a forest plot of OR
estimates from these studies. The combined OR estimate
was 2.458 (95% CI 2.010–3.006) with no evidence of
Table 3 Indacaterol on dyspnea as measured by the TDI
Study Treatment arms TDI at week 12
Patients, na TDI total scoreb Number of patients with TDI ≥1
Donohue [5] Indacaterol 150 μg od 355 2.09 (-8, 9) 209
Indacaterol 300 μg od 363 2.40 (-9, 9) 239
Tiotropium 18 μg od 360 1.89 (-6, 9) 198
Placebo 326 1.19 (-6, 9) 138
Dahl [6] Indacaterol 300 μg od 364 2.11 (-9, 9) 229
Indacaterol 600 μg od 348 2.10 (-7, 9) 202
Formoterol 12 μg bid 359 1.64 (-9, 9) 190
Placebo 343 0.87 (-9, 9) 138
Kornmann [7] Indacaterol 150 μg od 303 2.37 (-6, 9) 182
Salmeterol 50 μg bid 296 1.60 (-6, 9) 152
Placebo 286 0.87 (-9, 9) 113
Gotfried-1 [8] Indacaterol 75 μg od 150 1.36 (-6, 9) 73
Placebo 150 0.12 (-9, 9) 48
Gotfried-2 [8] Indacaterol 75 μg od 148 1.25 (-7, 9) 69
Placebo 149 0.83 (-6, 9) 53
Kinoshita [9] Indacaterol 150 μg od 108 2.16 (-3, 9) 66
Indacaterol 300 μg od 107 2.04 (-3, 9) 58
Placebo 102 0.88 (-6, 9) 40
a Number of patients evaluated for TDI total score at week 12 and included in the responder analysis.
b Values are mean (min, max) of raw and unadjusted TDI total score.
Han et al. BMC Pulmonary Medicine 2013, 13:26 Page 5 of 8
http://www.biomedcentral.com/1471-2466/13/26heterogeneity (P = 0.525, I2 = 0.000), again favoring pa-
tients who received indacaterol 300 μg once daily.
Discussion
The present meta-analyses combined data from existing
randomized placebo-controlled trials, using number of
patients achieving the minimum clinically important dif-
ference (MCID) for TDI score ≥1 as an outcome meas-
ure, and evaluated the efficacy of once-daily indacaterol
on TDI scores in patients with stable COPD. A favorableOdds Ratio
95% CI
Study name n
Gotfried study 1 [8]







Figure 1 Forest plot of odds ratios and 95% confidence intervals. Rela
more likely to achieve TDI score equal to or greater than one unit.effect was consistently obtained for indacaterol over
placebo: 75 μg od OR 1.784 (95% CI 1.282 to 2.482); 150
μg od OR 2.149 (95% CI 1.746 to 2.645); and 300 μg od
OR 2.458 (95% CI 2.010 to 3.006). A trend of increasing
patient benefit was observed as indacaterol doses
increased.
Recent guidelines recommend regular use of broncho-
dilators, such as indacaterol, as a long-term maintenance
treatment of airflow limitation in COPD [1]. The extent
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Figure 2 Meta-analysis of three randomized trials compared indacaterol 150 μg once daily with placebo. Relative to placebo, patients
receiving indacaterol 150 μg once daily are more likely to achieve TDI score equal to or greater than one unit.
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http://www.biomedcentral.com/1471-2466/13/26COPD is well studied [4,5,21-24]. In these phase III
studies, indacaterol provided 24-h bronchodilation on
once-daily dosing with an effect that was sustained dur-
ing treatment for up to one year. However, from the
patients’ viewpoint, it may be more important to know
whether this therapy improves dyspnea associated with
daily activities, and these meta-analyses of available ran-
domized placebo-controlled trials comparing indacaterol
with placebo allows us to examine the efficacy of
indacaterol on this important patient outcome. In all tri-
als included in the meta-analyses, dyspnea was assessed
using validated multidimensional instruments of BDI
and TDI that are widely used to measure treatment
effects in COPD [13-17]. When data were analyzed for a
pre-determined outcome, i.e. the number of patients
responding with a change of TDI equal to or greater
than the minimum clinically important difference MCID
(a ‘responder analysis’), a favorable effect was obtained












Figure 3 Meta-analysis of three randomized trials compared indacate
receiving indacaterol 300 μg once daily are more likely to achieve TDI scorestimates of the meta-analyses are largely consistent with
the results from the individual studies, in which the ORs
for patients achieving a MCID in the indacaterol group
compared with the placebo group varied from 1.582 to
2.015 for the 75 μg dose (Figure 1) [8], 1.950 to 2.303
for the 150 μg dose (Figure 2) [5,7], and 2.520 to 2.626
for the 300 μg dose (Figure 3) [5,6], with a exception of
the Asian study [9]. It becomes apparent that patients
receiving indacaterol had clinically significant improve-
ments in symptoms of dyspnea compared to placebo
over 12 weeks of treatment.
The overall odds ratio for response in TDI appeared to
vary depending on indacaterol doses, and tended to
increase with increasing indacaterol doses. Additionally,
the percentage of patients who exceeded the one unit of
the MCID in TDI varied in different indacaterol doses.
The percentage in the analysis of indacaterol 75 μg
once daily was 48%, compared with 34% in placebo.
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versus 41%) and indacaterol 300 μg doses (63% versus
41%). Renard and his colleagues recently performed a
model based analysis of the bronchodilatory dose re-
sponse to indacaterol in patients with COPD [25]. The
analysis demonstrated that indacaterol dosages of 75 μg
once daily and above achieved minimal clinically import-
ant improvements in predicted trough FEV1 response,
although dosages of 150 μg and 300 μg once daily pro-
vided optimum bronchodilation. The analysis also dem-
onstrated that disease severity, as determined by FEV1,
significantly affected dose response, suggesting that
higher doses may be required in patients with more se-
vere COPD to achieve optimal reduction of dyspnea.
In six trials included in the meta-analysis (n=5405),
patients with COPD who received indacaterol 75 μg, or
150 μg, or 300 μg od had a significantly higher trough
FEV1 than placebo after at least 12 weeks, with
indacaterol increasing trough FEV1 by 120ml to 200 ml
over placebo at week 12 [5-9]. The overall improvement
in FEV1, though modest, may be sufficient to decrease
the extent of hyperinflation which contributes to the
sensation of dyspnea [26-29]. A better indicator of the
effect of a bronchodilator on hyperinflation (and there-
fore the sensation of dyspnea) is perhaps inspiratory
capacity. One could hypothesize that the prolonged
bronchodilation observed with indacaterol would be
associated with reductions of air trapping, and therefore
reductions in hyperinflation, which would then be
reflected in improvements in the sensation of dyspnea.
There are relatively few indacaterol studies that included
both an assessment of inspiratory capacity and of dys-
pnea, however, two short-term exercise studies compar-
ing the 300 μg dose of indacaterol with placebo have
been published [30,31]. The BDI/TDI was included in
one of the studies, an improvement of 182 ml in resting
inspiratory capacity after 14 days (p<0.05 vs. placebo)
was associated with a change of TDI total score of +3.33
(p<0.01 vs. placebo) [31], providing indirect evidence to
support the hypothesis.
Conclusions
Once daily indacaterol provides clinically significant im-
provements in dyspnea compared with placebo after 12
weeks of treatment. Incremental benefits in TDI were
observed with increasing doses of indacaterol. Indaca-
terol may provide patients and physicians with a useful
treatment option in symptomatic patients with dyspnea.
Further studies, that investigate the relationship between
disease severity as determined by FEV1 and dose re-
sponse to indacaterol in terms of dyspnea, are needed to
specifically address the question whether higher doses
are required in patients with more severe COPD to
achieve optimal reduction of dyspnea.Abbreviations
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